Region II Basketball
Division 4 Boys Semifinals
Potomac Falls 62, Broad Run 51
The Skinny: Lukas Mihailovich scores 24 to lead the Panthers to the school's first ever state basketball playoff appearance since the school opened in 1997. Broad Run, which fell behind 7-0 to start and never led in the contest, has been waiting 41 years for a trip to States -- since the school opened in 1969! Kevin
Thursday, February 25, 2010
Basketball: Regional Playoff Scoreboard
Region II Basketball
Division 4 Boys Semifinals
Potomac Falls 62, Broad Run 51
Division 4 Girls Semifinals
Freedom 49, Loudoun County 40
Liberty 58, Potomac Falls 50
Check back for The Skinny and then boxes and also a full game story from PF-BR boys by Dan Sousa and game reports from the girls contests plus photos and video interviews from the boys game
Division 4 Boys Semifinals
Potomac Falls 62, Broad Run 51
Division 4 Girls Semifinals
Freedom 49, Loudoun County 40
Liberty 58, Potomac Falls 50
Check back for The Skinny and then boxes and also a full game story from PF-BR boys by Dan Sousa and game reports from the girls contests plus photos and video interviews from the boys game
New Mexico/Texas GOP Preview
Tomorrow we're going to have 2012 Republican primary numbers for Texas and New Mexico.
Here are some clues:
-The same candidate leads (by a small margin) in both states.
-In each state there is someone who comes in a close second and someone who comes in a more distant third. But it's a different candidate in each state.
Have fun guessing and we'll have the numbers tomorrow!
Here are some clues:
-The same candidate leads (by a small margin) in both states.
-In each state there is someone who comes in a close second and someone who comes in a more distant third. But it's a different candidate in each state.
Have fun guessing and we'll have the numbers tomorrow!
Merck Puts Up Its Asset-Sale Shingle
Big Pharma has been slow to adopt out-licensing strategies for a plethora of reasons: fear it will regret giving up something that could turn out to be a hit, the perception that out-licensed compounds are tainted, and an ingrained mentality that it could afford to develop everything worthwhile on its own.
Merck is the latest company to change its tune in the face of a resource-constrained reality however; Lilly, Pfizer and others started earlier, by far, as IN VIVO has long tracked. At Elsevier's Pharmaceutical Strategic Outlook conference Thursday morning in NY, David Nicholson, the company's new SVP and head of Worldwide Licensing and Knowledge Management, gave the largely biotech and Big Pharma audience a message loud and clear: Merck's new out-licensing department is open for business-or will be shortly. "We have set up an out-licensing group, headed by Meeta Chatterjee," and are now looking at "what we want to out-license" and "how," he said in a talk with Elsevier's Roger Longman.
"In the past, Merck didn't out-license because out-licensing was traditionally used to jettison "rubbish," but that is not the case anymore," noted Nicholson, who previously headed worldwide
licensing at Schering-Plough. The company has some very attractive assets, but there is "no way Merck can afford to develop everything" in its R&D program. "Our R&D model is to generate a lot of output—more than we can deal with. So we have to make some tough choices and it poses the question: What do we do with these other assets?" And who might be potential in-licensors? Take note: Merck's not only interested in talking to biotechs and small pharma—its Big Pharma competitors could take a look too.
Details have yet to be worked out – Merck's looking at the best business models and deal structures for outlicensing and "brainstorming" ideas. And the company is generating a list of out-licensing assets.
Meanwhile, its in-licensing program is also moving forward. Now that its merger with Schering is completed, it's finalizing a list of its revamped pipeline, which it will announce in the next few weeks, and shortly after that it will "be able to talk to the world," Nicholson said.
Nicholson also spoke –albeit generally-- about Merck's partnership strategy going forward, i.e. biotechs will remain an incredibly important to Merck, because "the vast majority of new science is done outside Merck's walls," he said. "There are more opportunities outside than inside," and Merck wants to partner with all kinds of technologies, companies, and at all stages of development."
That includes externalizing discovery- a hot topic within Big Pharma at the moment, especially in light of a recent Morgan Stanley report, which argued that Big Pharma isn't doing worthwhile research and should evolve its "R&D" model to an "S&D" or search and develop model. Nicholson quarreled with the report's conclusions, but noted it did raise "interesting questions" about how much discovery research pharma should be doing internally versus externally.
Nicholson's message –a willingness to work with new kinds of partners in new ways--wasn't new for Merck – but it honed in on a trend that's been ongoing in Big Pharma for several years now, and practiced with more urgency as patent cliffs loom: In a growth constrained reality, companies need to evaluate what they can and can't afford to do internally and work with partners in new ways as they become more cost efficient and upgrade pipelines.
--Wendy Diller
Merck is the latest company to change its tune in the face of a resource-constrained reality however; Lilly, Pfizer and others started earlier, by far, as IN VIVO has long tracked. At Elsevier's Pharmaceutical Strategic Outlook conference Thursday morning in NY, David Nicholson, the company's new SVP and head of Worldwide Licensing and Knowledge Management, gave the largely biotech and Big Pharma audience a message loud and clear: Merck's new out-licensing department is open for business-or will be shortly. "We have set up an out-licensing group, headed by Meeta Chatterjee," and are now looking at "what we want to out-license" and "how," he said in a talk with Elsevier's Roger Longman.
"In the past, Merck didn't out-license because out-licensing was traditionally used to jettison "rubbish," but that is not the case anymore," noted Nicholson, who previously headed worldwide
licensing at Schering-Plough. The company has some very attractive assets, but there is "no way Merck can afford to develop everything" in its R&D program. "Our R&D model is to generate a lot of output—more than we can deal with. So we have to make some tough choices and it poses the question: What do we do with these other assets?" And who might be potential in-licensors? Take note: Merck's not only interested in talking to biotechs and small pharma—its Big Pharma competitors could take a look too.Details have yet to be worked out – Merck's looking at the best business models and deal structures for outlicensing and "brainstorming" ideas. And the company is generating a list of out-licensing assets.
Meanwhile, its in-licensing program is also moving forward. Now that its merger with Schering is completed, it's finalizing a list of its revamped pipeline, which it will announce in the next few weeks, and shortly after that it will "be able to talk to the world," Nicholson said.
Nicholson also spoke –albeit generally-- about Merck's partnership strategy going forward, i.e. biotechs will remain an incredibly important to Merck, because "the vast majority of new science is done outside Merck's walls," he said. "There are more opportunities outside than inside," and Merck wants to partner with all kinds of technologies, companies, and at all stages of development."
That includes externalizing discovery- a hot topic within Big Pharma at the moment, especially in light of a recent Morgan Stanley report, which argued that Big Pharma isn't doing worthwhile research and should evolve its "R&D" model to an "S&D" or search and develop model. Nicholson quarreled with the report's conclusions, but noted it did raise "interesting questions" about how much discovery research pharma should be doing internally versus externally.
Nicholson's message –a willingness to work with new kinds of partners in new ways--wasn't new for Merck – but it honed in on a trend that's been ongoing in Big Pharma for several years now, and practiced with more urgency as patent cliffs loom: In a growth constrained reality, companies need to evaluate what they can and can't afford to do internally and work with partners in new ways as they become more cost efficient and upgrade pipelines.
--Wendy Diller
NC Filing Roundup
Quick update on North Carolina filing:
-I know what legislative primary I'll be most interested in on election night- former House Speaker Richard Morgan is challenging incumbent Harris Blake for the State Senate. I have a hard time seeing Morgan winning that one but it should be interesting to watch.
-It's been a very good couple of days for House Democratic recruitment. They got candidates in three of the races where the GOP candidate won by the smallest margin in 2008. Robin Anderson will challenge Nelson Dollar, Debra McHenry is taking on Paul Stam, and John Eaker will face Pearl Burris-Floyd. They also got a candidate- Mary Accor- who will challenge Tim Moore in the most Democratic leaning district currently held by a Republican. Moore was unopposed two years ago.
-The US Senate primaries on both sides have gotten more crowded, with Ann Worthy getting in on the Democratic side and Larry Linney for the Republicans.
-Heath Shuler has drawn a primary challenger in Aixa Wilson. That now makes 7 of 13 North Carolina House members facing an election in May.
Tomorrow's the last day!
-I know what legislative primary I'll be most interested in on election night- former House Speaker Richard Morgan is challenging incumbent Harris Blake for the State Senate. I have a hard time seeing Morgan winning that one but it should be interesting to watch.
-It's been a very good couple of days for House Democratic recruitment. They got candidates in three of the races where the GOP candidate won by the smallest margin in 2008. Robin Anderson will challenge Nelson Dollar, Debra McHenry is taking on Paul Stam, and John Eaker will face Pearl Burris-Floyd. They also got a candidate- Mary Accor- who will challenge Tim Moore in the most Democratic leaning district currently held by a Republican. Moore was unopposed two years ago.
-The US Senate primaries on both sides have gotten more crowded, with Ann Worthy getting in on the Democratic side and Larry Linney for the Republicans.
-Heath Shuler has drawn a primary challenger in Aixa Wilson. That now makes 7 of 13 North Carolina House members facing an election in May.
Tomorrow's the last day!
Swim: Loudoun Showed Its Depth at AA State Swim Meet
(Feb. 25, 2010) - Loudoun swimmers certainly made a big splash with the strong finish of the Broad Run High School boys and Briar Woods girls at the AA state meet over the weekend, but the depth of Loudoun swimming showed all the way through the finals which were swam in two sections.
While they may have not scored in the top eight, those in the first finals had fast times, advanced after
While they may have not scored in the top eight, those in the first finals had fast times, advanced after
Basketball: Region II Semifinals Tonight
(Feb. 25, 2010) - The Region II basketball Division 4 semifinals are scheduled tonight with a pair of huge rematches from the Dulles District tournament and historic game for the Potomac Falls girls.
If you can't attend your favorite game or want to keep up with the others ... sign up to follow our Twitter account and activate your mobile number: http://twitter.com/VivaLoudoun
The rematches are
If you can't attend your favorite game or want to keep up with the others ... sign up to follow our Twitter account and activate your mobile number: http://twitter.com/VivaLoudoun
The rematches are
Subscribe to:
Posts (Atom)